

This communication should be viewed by:

Primary Care Providers
Behavioral Health Providers
Clinical staff

Pharmaceutical Policy Updates Effective September 1, 2025

To view all current MVP Health Care® (MVP) Medical policies, *Sign In* at mvphealthcare.com and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes** – Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies are effective September 1, 2025, and will be available for viewing on or before August 1, 2025. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status	Pharmaceutical Policy Name	Status
Adakveo	Updated	Hemophilia Gene Therapy Part B	Reviewed/No changes
Adakveo Part B	New	Hereditary Angioedema	Updated
Beqvez	Archived	Idiopathic Pulmonary Fibrosis	Updated
Beqvez Part B	Archived	Lyfgenia	No changes
C. Difficile Drug Therapy	Reviewed/No changes	Lyfgenia Part B	Updated
C. Difficile Drug Therapy Part B	Reviewed/No changes	Mulpleta/Doptelet	Updated
Casgevy	Updated	Orphan Drugs and Biologicals	Updated
Casgevy Part B	Updated	Orphan Drugs and Biologicals Part B	Updated
Colony Stimulating Factor	Reviewed/No changes	Remestemcel	
Cystic Fibrosis Select Agents for Inhalation	Reviewed/No changes	Effective July 1, 2025	
Cystic Fibrosis Select Oral Agents	Updated	Remestemcel Part B	New
Gaucher's Disease Type 1 Treatment	Updated		
Hemophilia Gene Therapy	Updated	Select Chelating Agents	Reviewed/No changes
		Select injectable for Asthma	Updated

To view all communications, visit mvphealthcare.com/FastFax